DK2118128T3 - Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1 - Google Patents

Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1

Info

Publication number
DK2118128T3
DK2118128T3 DK08727588.9T DK08727588T DK2118128T3 DK 2118128 T3 DK2118128 T3 DK 2118128T3 DK 08727588 T DK08727588 T DK 08727588T DK 2118128 T3 DK2118128 T3 DK 2118128T3
Authority
DK
Denmark
Prior art keywords
lage
eso
fusion proteins
tumor rejection
rejection antigens
Prior art date
Application number
DK08727588.9T
Other languages
Danish (da)
English (en)
Inventor
Normand Blais
Martine Boyer
Vincent Brichard
Jamila Louahed
Denis Martin
Remi M Palmantier
Clement Rioux
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700759A external-priority patent/GB0700759D0/en
Priority claimed from GB0701262A external-priority patent/GB0701262D0/en
Priority claimed from GB0709707A external-priority patent/GB0709707D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK2118128T3 publication Critical patent/DK2118128T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK08727588.9T 2007-01-15 2008-01-11 Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1 DK2118128T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0700759A GB0700759D0 (en) 2007-01-15 2007-01-15 Novel fusion protein
GB0701262A GB0701262D0 (en) 2007-01-23 2007-01-23 Vaccine
US91492507P 2007-04-30 2007-04-30
US91484807P 2007-04-30 2007-04-30
GB0709707A GB0709707D0 (en) 2007-05-21 2007-05-21 Novel fusion protein
PCT/US2008/050879 WO2008089074A2 (en) 2007-01-15 2008-01-11 Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1

Publications (1)

Publication Number Publication Date
DK2118128T3 true DK2118128T3 (da) 2013-02-18

Family

ID=41111108

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08727588.9T DK2118128T3 (da) 2007-01-15 2008-01-11 Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1

Country Status (15)

Country Link
EP (1) EP2118128B1 (enExample)
JP (1) JP2010532656A (enExample)
KR (1) KR20090122426A (enExample)
BR (1) BRPI0806501A2 (enExample)
CA (1) CA2674458A1 (enExample)
DK (1) DK2118128T3 (enExample)
EA (1) EA016818B1 (enExample)
ES (1) ES2398492T3 (enExample)
HR (1) HRP20130022T1 (enExample)
MX (1) MX2009007572A (enExample)
PE (1) PE20081687A1 (enExample)
PL (1) PL2118128T3 (enExample)
SI (1) SI2118128T1 (enExample)
TW (1) TW200902049A (enExample)
WO (1) WO2008089074A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
BRPI1009873A2 (pt) 2009-03-17 2016-03-08 Glaxosmithkline Biolog Sa detecção aperfeiçoada de expressão gênica
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
AU2012302778B2 (en) * 2011-08-31 2016-11-24 Mie University Vaccine preparation for cancer treatment
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
CN105555756B (zh) * 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
EP3053592B1 (en) 2013-10-01 2025-04-23 Mie University T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
CN108697777A (zh) 2016-02-08 2018-10-23 国立大学法人三重大学 对免疫检查点抑制剂抵抗性肿瘤的t细胞输注疗法的预处理药物
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CA3119865A1 (en) * 2018-11-23 2020-05-28 Strike Pharma Ab Bi-specific conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06205672A (ja) * 1992-03-19 1994-07-26 Nippon Zeon Co Ltd 日本脳炎ウイルス及びｂ型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US7060279B2 (en) * 2000-03-30 2006-06-13 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
CA2551644C (en) * 2003-12-24 2014-03-04 Cerus Corporation Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of usethereof
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
BRPI0518933A2 (pt) * 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
US20090186049A1 (en) * 2006-05-26 2009-07-23 Vincent Brichard Method of treating mage positive cancer
US20080187535A1 (en) * 2007-01-15 2008-08-07 Normand Blais Vaccine

Also Published As

Publication number Publication date
WO2008089074A3 (en) 2008-12-31
EA200900738A1 (ru) 2010-02-26
EA016818B1 (ru) 2012-07-30
HRP20130022T1 (hr) 2013-02-28
TW200902049A (en) 2009-01-16
CA2674458A1 (en) 2008-07-24
KR20090122426A (ko) 2009-11-30
PL2118128T3 (pl) 2013-03-29
PE20081687A1 (es) 2008-12-25
ES2398492T3 (es) 2013-03-19
WO2008089074A9 (en) 2012-07-12
WO2008089074A2 (en) 2008-07-24
BRPI0806501A2 (pt) 2014-04-22
EP2118128B1 (en) 2012-11-07
JP2010532656A (ja) 2010-10-14
SI2118128T1 (sl) 2013-02-28
MX2009007572A (es) 2009-10-13
EP2118128A2 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
SI2118128T1 (sl) Fuzijski proteini, ki obsegajo tumorska zavrnitvena antigena NY-ESO-1 in LAGE-1
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
IL260184B (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
PL2942355T3 (pl) Nie-hemolityczne białka fuzyjne llo i ich zastosowanie
DK1844074T3 (da) Humane antistoffer og proteiner
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
DK2176296T3 (da) Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
NO20080692L (no) SP35 antistoffer og anvendelse derav
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
IL210768B (en) Antibodies targeting complement protein c5 and compositions comprising them
IL191759A (en) Ganaxolone formulations and methods for the making and use thereof
HUE037061T2 (hu) Specifikusan kötõdõ fehérjék és alkalmazásuk
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK2068887T3 (da) SP35-antistoffer og anvendelser heraf
PL2493925T3 (pl) Białka wiążące antygen ludzkiej IL-23
DK3002298T3 (da) Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
PT1920065T (pt) Anticorpos anti-alfavbeta6 e suas utilizações
HUE038501T2 (hu) Antitest készítmények
EP2173377A4 (en) ANTIBODY ENDOSTATIN FUSION PROTEIN AND ITS VARIATIONS
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
HUE037307T2 (hu) Tumor-asszociált antigének felismerése diagnózishoz és terápiához
DK2152748T3 (da) Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf
IL205705A (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
DK2061814T3 (da) Antistoffer og immunokonjugater og anvendelse deraf.